Lisata Therapeutics (LSTA) to Release Earnings on Thursday

Lisata Therapeutics (NASDAQ:LSTA) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:30 PM ET.

Lisata Therapeutics Stock Performance

Shares of NASDAQ:LSTA opened at $4.40 on Tuesday. Lisata Therapeutics has a 52 week low of $1.81 and a 52 week high of $4.89. The firm has a market cap of $38.81 million, a PE ratio of -2.07 and a beta of 1.23. The firm’s fifty day moving average is $3.21 and its 200-day moving average is $2.63.

Institutional Trading of Lisata Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LSTA. Cerity Partners LLC bought a new stake in Lisata Therapeutics during the second quarter worth $32,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Lisata Therapeutics in the third quarter valued at about $37,000. Finally, Renaissance Technologies LLC lifted its position in shares of Lisata Therapeutics by 6.1% during the fourth quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock valued at $230,000 after purchasing an additional 7,093 shares in the last quarter. 8.94% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Brookline Capital Acquisition downgraded Lisata Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Thursday, January 22nd. Finally, Zacks Research lowered Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $23.50.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.